The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Size: px
Start display at page:

Download "The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy."

Transcription

1 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. A Proposal for a New Staging System. Toyonori Tsuzuki, Toshinori Nishikimi, Yota Murase, Hidehiro Iwata Aichi Medical University Hospital

2 The 30 th European Congress of Pathology Conflict of Interest (COI) Presenter: Toyonori Tsuzuki The author has no conflict of interest to disclose with respect to this presentation. Department of Surgical Pathology Aichi Medical University Hospital

3 Background The AJCC/UICC TNM classification is the gold standard to predict bladder cancer outcome. The paradigm of pathological stage (pt) categorization in bladder cancer remains the depth of tumor invasion into the different histologic layers of the bladder wall. However, the structure of these layers differs from their anatomic site.

4

5 AJCC/UICC pt staging 8 th edition TX T0 Ta Tis T1 T2 Primary tumor Primary tumor cannot be assessed No evidence of primary tumor Noninvasive papillary carcinoma Carcinoma in situ Tumor invades subepithelial connective tissue (lamina propria) Tumor invades musclularis propria T2a Tumor invades superficial muscularis propria (inner half) T2b Tumor invades deep muscularis propria (outer half) T3 T4 Tumor invades perivesical tissue T3a Microscopically T3b Macroscopically (extravesical mass) Tumor invades any of the following: prostatic stroma, uterus, vagina, pelvic wall, and abdominal wall T4a T4b Tumor invades prostatic stroma* or uterus or vagina Tumor invades pelvic wall or abdominal wall

6 Background The boundary of muscularis propria and perivesical tissue is commonly ill defined. The distinction on microscopic and macroscopic (pt3a vs pt3b) perivesical tissue is usually subjective. Therefore, the current TNM staging system demonstrates wide prognostic variability within each primary tumor stage.

7

8 Am J Surg Pathol. 2014;38 :167-75

9 Am J Surg Pathol. 2014;38 :167-75

10 Background The boundary of muscularis propria and perivesical tissue is commonly ill defined. The distinction on microscopic and macroscopic (pt3a vs pt3b) perivesical tissue is usually subjective. Therefore, the current TNM staging system demonstrates wide prognostic variability within each primary tumor stage.

11 Aim To develop a new pt staging system improving the objectivity and accuracy of prognosis in bladder cancer by integrating the depth of tumor invasion.

12 Methods We enrolled 117 muscle invasive urothelial carcinoma of the bladder patients between May 2004 to December No patients had distant metastasis. No patients received adjuvant and/or neoadjuvant chemotherapy. We reviewed the all slides and selected the slides showing deepest tumor invasion from the normal urothelium.

13 Methods pt2 (AJCC/UICC) (Tumor invades into the musclaris propria.) pt3(ajcc/uicc) (Tumor invades into the perivesicular tissue.) Normal urothelium The depth of tumor invasion was measured from the normal urothelium to the deepest tumor invasion.

14

15 Results Clinical characteristics No. patients 117 Male : female ratio 78:39 Patient s age (median) (71) Follow-up duration (median) months (32) No. developed recurrence 72 No. died of the disease 55 No. died of other causes 14

16 Analyzed prognostic valuables Depth of tumor invasion (mm) Pathological T stage (pt) 1973WHO grade (G1, G2, G3) Lymphovascular invasion Lymph node metastasis Concomitant CIS Age

17 Pathological characteristics Depth of tumor invasion(median) mm (10.80) pt2:pt3 38: WHO grade G2 28 G3 89 Lympho-vascular invasion Present 59 Absent 58 Lymph node metastasis Present 14 Absent 103 Concomitant CIS Present 33 Absent 84

18 Cutoff value of depth of tumor invasion Harrell C-index in COX model Harrell C-index in Fine and Gray model

19 Univariate Multivariate Pathological factor Categori N Hazard Ratio 95% CI Pvalue* Hazard Univariate Ratio 95% CI Pvalue* Depth of tumor invasion < <= (1.27, 3.51) (1.11, 3.21) Lympho-vascular invasion V V1/V (1.06, 2.84) (0.84, 2.39) Lymph node metastasis yes 14 1 no (0.29, 1.12) (0.35, 1.47) pt pt pt (0.85, 2.49) (0.60, 1.95) Age < <= (0.87, 3.08) (0.83, 3.01) WHO grade G G (0.68, 2.21) (0.58, 1.94) CIS yes 33 1 no (0.60, 1.78) (0.61, 1.90) Multivariate tor Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* n < <= (1.27, 3.51) (1.11, 3.21) sion V V1/V (1.06, 2.84) (0.84, 2.39) is yes 14 1 no (0.29, 1.12) (0.35, 1.47)

20 Pathological factor Categori N Pr > ChiSq Hazard Ratio 95% CI Categori N Pr > ChiSq Hazard Ratio Depth of tumor invasion < <= Lympho-vascular invasion V V1/V Lymph node metastasis yes 14 1 no < pt pt pt Age < <= WHO V0 grade 59G G CIS yes 33 1 no % CI 10<= V1/V

21 Univariate Multivariate Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* Univariate Multivariate Pathological factor Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* Depth of tumor invasion < <= (1.23, 3.52) (1.12, 3.36) Lmpho-vascular invasion V <10 55 V1/V Lymph node metastasis yes 14 1 (1.01, 2.81) (0.80, 2.40) no (0.25, 0.97) (0.28, 1.22) pt pt pt (0.76, 2.26) (0.55, 1.82) Age V0 59 < <= (0.91, 3.41) (0.93, 3.58) WHO grade G G (0.59, 1.97) (0.50, 1.73) CIS yes 14 yes no (0.71, 2.30) (0.70, 2.38) <= (1.23, 3.52) (1.12, 3.36) V1/V (1.01, 2.81) (0.80, 2.40)

22 Conclusions The depth of tumor invasion (<10 mm vs. >10 mm) was an independent prognostic factor in DFS, CSS, and OS. The depth of tumor invasion can be a novel staging system for bladder cancer, that is more objective and accurate than the current AJCC/UICC staging system in muscle invasive bladder cancer.

23 Thank you

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1) Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

The pathology of bladder cancer

The pathology of bladder cancer 1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new

More information

Urinary Bladder, Ureter, and Renal Pelvis

Urinary Bladder, Ureter, and Renal Pelvis Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

BLADDER CANCER EPIDEMIOLOGY

BLADDER CANCER EPIDEMIOLOGY BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel

More information

Carcinoma of the Renal Pelvis and Ureter Histopathology

Carcinoma of the Renal Pelvis and Ureter Histopathology Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

TOPICS FOR DISCUSSION

TOPICS FOR DISCUSSION INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los

More information

UICC TNM 8 th Edition Errata

UICC TNM 8 th Edition Errata UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

UICC TNM 8 th Edition Errata

UICC TNM 8 th Edition Errata UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological

More information

A215- Urinary bladder cancer tissues

A215- Urinary bladder cancer tissues A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90

More information

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital. Male genital tract tumors Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital. adenocarcinoma Prostate Cancer most common male cancer in western countries more detected in

More information

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,

More information

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4). GU Cancer Staging: Updates and Challenging Areas 13 th Current Issues in Surgical Pathology San Francisco, CA June 5, 2010 Jeffry P. Simko, PhD, MD Associate Professor Departments of Urology and Anatomic

More information

Urinary Bladder, Ureter, and Renal Pelvis

Urinary Bladder, Ureter, and Renal Pelvis Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures

More information

BLADDER CANCER: PATIENT INFORMATION

BLADDER CANCER: PATIENT INFORMATION BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,

More information

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018 Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported

More information

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix. Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying

More information

A patient with recurrent bladder cancer presents with the following history:

A patient with recurrent bladder cancer presents with the following history: MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from

More information

Upper urinary tract urothelial carcinomas (UTUC)

Upper urinary tract urothelial carcinomas (UTUC) Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida

More information

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT) Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of

More information

Management of Vulvar Cancer: How to Handle Close Margins?

Management of Vulvar Cancer: How to Handle Close Margins? Management of Vulvar Cancer: How to Handle Close Margins? Sven Mahner, MD Department of Gynecology and Obstetrics University of Munich AGO Study Group Munich, Germany Surgical Resection of Vulvar Cancer

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Case Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case

More information

KEYWORDS Bladder cancer, Transitional cell carcinoma, Magnetic resonance imaging, staging, Tumor node metastasis

KEYWORDS Bladder cancer, Transitional cell carcinoma, Magnetic resonance imaging, staging, Tumor node metastasis DIAGNOSTIC ACCURACY OF MRI IN DIFFERENTIATING NON-MUSCLE INVASIVE FROM MUSCLE INVASIVE BLADDER CARCINOMA TAKING HISTOPATHOLOGICAL STAGING AS A STANDARD. Syed Muhammad Faiq 1,Khujasta Mehtab 1,Nazish Naz

More information

Staging and reporting of urothelial carcinoma of the urinary bladder

Staging and reporting of urothelial carcinoma of the urinary bladder & 2009 USCAP, Inc All rights reserved 0893-3952/09 $32.00 www.modernpathology.org Staging and reporting of urothelial carcinoma of the urinary bladder Liang Cheng 1,2, Rodolfo Montironi 3, Darrell D Davidson

More information

Definition of Synoptic Reporting

Definition of Synoptic Reporting Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are

More information

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and

More information

CODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser

CODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic

More information

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda Collecting Cancer Data: Bladder March 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding Moment Bladder Overview Multiple Primary Histology Rules Collaborative Stage Data Collection System Diagnostic,

More information

Prognostic factors of genitourinary tumors: Do we have to care?

Prognostic factors of genitourinary tumors: Do we have to care? Prognostic factors of genitourinary tumors: Do we have to care? Jae Y. Ro, MD, PhD Professor and Director of Surgical Pathology The Methodist Hospital, Weill Medical College of Cornell University, Houston,

More information

Understanding Your Pathology Report

Understanding Your Pathology Report Understanding Your Pathology Report Because every person s breast cancer is unique, it s important to understand the underlying biology of your tumor to personalize your treatment plan. Your physicians

More information

Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease

Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging

More information

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

Patient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3)

Patient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3) Carcinoma of the Bladder Histopathology Reporting Guide Cystectomy, Cystoprostatectomy and Diverticulectomy Specimen Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Pathology Driving Decisions

Pathology Driving Decisions Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He

More information

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS

More information

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification

More information

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients

More information

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI

More information

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam

More information

Key words: gastric cancer, lymphovascular invasion, recurrence

Key words: gastric cancer, lymphovascular invasion, recurrence Key words: gastric cancer, lymphovascular invasion, recurrence 139 (2177) Table I Relationship between clinicopathologic factors and lymphatic invasion in 2146 patients with gastric cancer Factors P-value

More information

Etiology and diagnosis of bladder cancer

Etiology and diagnosis of bladder cancer Etiology and diagnosis of bladder cancer Introduction Incidence: the most common urothelial tumor, representing the 2 nd most common urological tumor in men (4 th in overall frequency) and the 1 st in

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do? Exercise 1 Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do? : 1. I mention both categories that are in consideration, e.g. pt1-2 2. I classify as

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer 대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer

More information

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education

More information

Gastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW

Gastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW Gastric Cancer Staging AJCC eighth edition Duncan McLeod Westmead Hospital, NSW Summary of changes New clinical stage prognostic groups, ctnm Postneoadjuvant therapy pathologic stage groupings, yptnm -

More information

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES 25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES SPEAKER DR DEEPAK ABROL CLINICAL ONCOLOGIST JAND K HEALTH SERVICES CONSULTANT ONCOLOGIST MAHARISHI DAYANAND HOSPITAL AND MEDICAL RESEARCH CENTER

More information

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim. www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2

More information

A schematic of the rectal probe in contact with the prostate is show in this diagram.

A schematic of the rectal probe in contact with the prostate is show in this diagram. Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview

More information

Gastric Cancer Histopathology Reporting Proforma

Gastric Cancer Histopathology Reporting Proforma Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate

More information

Can MRI Improve Triage of Bladder Cancer Patients. John Chang, M.D., Ph.D. Banner MD Anderson Cancer Center

Can MRI Improve Triage of Bladder Cancer Patients. John Chang, M.D., Ph.D. Banner MD Anderson Cancer Center Can MRI Improve Triage of Bladder Cancer Patients John Chang, M.D., Ph.D. Banner MD Anderson Cancer Center None Financial Disclosures MRI for Bladder Cancer Background Bladder cancer staging and treatment

More information

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone

More information

Attachment #2 Overview of Follow-up

Attachment #2 Overview of Follow-up Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer

More information

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the

More information

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

Neoplasms of the Prostate and Bladder

Neoplasms of the Prostate and Bladder Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution

More information

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau

More information

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan

More information

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

L ARYNX S TAGING F ORM

L ARYNX S TAGING F ORM CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left

More information

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney. Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme

More information

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis

Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis 73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled

More information

Large blocks in prostate and bladder pathology

Large blocks in prostate and bladder pathology Large blocks in prostate and bladder pathology Farkas Sükösd Department of Pathology, University of Szeged The history of the large block technique in radical prostatectomy and cystectomy The first large

More information

What is endometrial cancer?

What is endometrial cancer? Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women

More information

Haematuria and Bladder Cancer

Haematuria and Bladder Cancer Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

Bladder Cancer Early Detection, Diagnosis, and Staging

Bladder Cancer Early Detection, Diagnosis, and Staging Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

STAGE CATEGORY DEFINITIONS

STAGE CATEGORY DEFINITIONS CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c

More information

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details

More information

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura

More information

European Association of Urology. Pocket Guidelines edition

European Association of Urology. Pocket Guidelines edition European Association of Urology Pocket Guidelines 2012 edition Introduction The EAU Guidelines Office is pleased to present the 2012 edition of the Pocket Guidelines. These ultra-short versions of Europe

More information

UICC 8 th Edition Errata 25 th of May 2018

UICC 8 th Edition Errata 25 th of May 2018 UICC 8 th Edition Errata 25 th of May 2018 ions are in italics Head and Neck Tumours Page 19 Oral Cavity T2 T3 T4a Tumour 2 cm or less in greatest dimension and more than 5 mm but no more than 10 mm depth

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com

More information